Weekly Analysts’ Ratings Changes for Ralliant (RAL)

A number of firms have modified their ratings and price targets on shares of Ralliant (NYSE: RAL) recently:

• 5/13/2026 – Ralliant had its price target raised by Royal Bank Of Canada from $47.00 to $64.00. They now have a “sector perform” rating on the stock.
• 5/13/2026 – Ralliant had its price target raised by Oppenheimer Holdings, Inc. from $50.00 to $65.00. They now have an “outperform” rating on the stock.
• 5/13/2026 – Ralliant had its “buy” rating reaffirmed by Citigroup Inc..
• 5/13/2026 – Ralliant had its price target raised by Barclays PLC from $52.00 to $67.00. They now have an “overweight” rating on the stock.
• 5/13/2026 – Ralliant had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $68.00 price target on the stock, up from $53.00.
• 5/4/2026 – Ralliant had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 4/13/2026 – Ralliant was upgraded by Zacks Research from “strong sell” to “hold”.

Ralliant Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, June 8th. Ralliant’s payout ratio is presently 10.20%.

Insiders Place Their Bets

In other Ralliant news, SVP Karen M. Bick sold 5,485 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $45.00, for a total value of $246,825.00. Following the transaction, the senior vice president directly owned 46,756 shares in the company, valued at $2,104,020. The trade was a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.